Autoimmune Disease Therapeutics to 2016

• Publication date: May 2012

As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence an of improved understanding of autoimmu...

As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence an of improved understanding of autoimmune disease mechanisms and the availability of recombinant cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise of future improvements in outcomes for autoimmune disease patients. This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact on treatment options and the competitive landscape.

Highlights

• Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses their commercial potential
• Assesses existing and evolving immune disease mechanisms and treatment strategies
• Analyzes more than two dozen existing and emerging autoimmune disease targets and target-specific therapeutic drug products
• Evaluates regional and global opportunities for autoimmune therapeutics
• Provides market data and forecasts for six major autoimmune disease segments to 2016

Pathology Industry

Executive Summary

Autoimmune Therapeutics Segment Dynamics

Sector Market Dynamics
Patient Demographics and Growth
Chronic Disease and Self-administration
Managed Care and Prescribing Trends
Factors Limiting Growth
Industry Alignment and Competitive Landscape

Autoimmune Therapeutic Market Assessments

Arthritis
Disease Forms and Immune Mechanisms
Therapeutic Strategies
Disease Demographics and Growth
Key Approved Therapies
Development-stage Candidate Assessment
Market Factors
Commercial Outlook and Forecasts

Crohn’s Disease
Disease Incidence and Demographics
Current Generation Treatment Options
Therapies in Development
Market Factors
Commercial Outlook and Forecasts

Diabetes
Restoring Islet Cell Function
Therapies in Development
Commercial Outlook and Forecasts

Lupus
The Ongoing Unmet Need
Pipeline Candidates – A Ray of Hope
Market Factors
The Potential for a Lupus-specific Therapy
Commercial Outlook and Forecasts

Multiple Sclerosis
Disease Mechanisms and Therapeutic Strategies
The Market Opportunity
Competitive Landscape
Development-stage Candidate Assessment
Market Factors
Commercial Outlook and Forecasts

Psoriasis
Therapeutic Options and Expanded Indications
Prescribing Trends and Drug Efficacy
Market Sector Factors
Development-stage Candidate Assessment
Commercial Outlook and Forecasts

Market Factors
Risk Factors
Clinical Trial Factors
Product Issues

Autoimmune Therapeutics – Company Profile